It is a hybrid capture panel designed for Analysis of Circulating cfDNA to Evaluate Somatic Status using the Unique Molecular Index (UMIs) for high sensitivity. MSK-ACCESS is 13% as large, captures 47% of all mutations detected by MSK-IMPACT.
CMO-CH is offered by the Center for Molecular Oncology (CMO) to MSK researchers for profiling white blood cell DNA to detect mutations in the most commonly altered (CH) associated genes.
What is the panel design?
596 targets capturing 58% of CH and 90.4% of CH-PD mutations identified in the latest CH dataset from 40K patients
Total size = 1,143 probes (0.14 Mb)
Full gene coverage for TP53, TET2, ASXL1, DNMT3A, PPM1D, CHEK2, ASXL1, ATM, SF3B1, SRSF2, U2AF1, and U2AF2•Additional targets with hotspot positions from IMPACT heme assay
SNP tiling around TP53, CBL, MPL, JAK2, EZH2, TET2, RUNX1, and ATM (+/-10kb) to identify allelic-imbalances
40 fingerprint SNPs that are shared with all other NGS assays (IMPACT, ACCESS, WES etc.) to detect sample mismatches
Voyager has all our configurations in the jinja template, it includes all the paths for various files and tools associated with the workflows, all location are on JUNO:
